The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context

Eur Heart J. 2021 Mar 31;42(13):1199-1202. doi: 10.1093/eurheartj/ehz916.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzhydryl Compounds / adverse effects*
  • Benzhydryl Compounds / therapeutic use
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucosides / adverse effects*
  • Glucosides / therapeutic use
  • Heart Failure* / drug therapy
  • Heart Failure* / prevention & control
  • Humans

Substances

  • Benzhydryl Compounds
  • Glucosides
  • dapagliflozin